Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz dose-finding study in early Alzheimer's disease
NL-OMON59080Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of efavirenz in Alzheimer's disease (AD), sponsored by Amsterdam University Medical Center. Started Oct 2024; status: recruiting.
02
Drugs
efavirenz
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON59080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59080.